The New Era for Respiratory Syncytial Virus Prevention for Infants in China:A Pediatricians’Perspective  

作　　者：Lisu Huang Zhimin Chen Mei Zeng 

机构地区：[1]Department of Infectious Disease,Children’s Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China [2]Department of Respiratory Diseases,Children’s Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China [3]Department of Infectious Diseases,Children’s Hospital of Fudan University,National Children’s Medical Center,Shanghai 201102,China

出　　处：《Infectious Diseases & Immunity》2024年第4期152-155,共4页感染性疾病与免疫（英文）

基　　金：supported by the Shanghai municipal three-year action plan for strengthening the construction of the public health system(2023-2025)GWVI-2.1.2.

摘　　要：This year marks a new era for respiratory syncytial virus(RSV)prevention for infants in China,as it is the first time since the detection of RSV that we have an option,namely,the long-acting monoclonal antibody nirsevimab,to prevent the infection and associated disease burden.We highly support the recent Chinese expert consensus that recommends nirsevimab as a new strategy for preventing RSV infections among infants born before or during their first RSV season,whether or not they have risk conditions putting them at higher risk of severe RSV disease.

关 键 词：PREVENTION RESPIRATORY MONOCLONAL 

分 类 号：R725.6[医药卫生—儿科]